A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-21 and is reviewed periodically as new material appears.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Never advertised, and practiced by only one individual who healed me, Dr. Quimby of Portland, ME., an old gentleman who had made it a research for twenty-five years, starting from the standpoint of magnetism thence going forward and leaving that behind. I discovered the art in a moment's time, and he acknowledged it to me; he died shortly after and since then, eight years, I have been founding and demonstrating the science.
In February 2023, Reuters reported that President Lula would meet with General Secretary of the Chinese Communist Party Xi Jinping during a four-day trip to China on 28 March to hold talks about trade, including green economy, digital inclusion, reindustrialization and the Russia-Ukraine War. On 17 March 2023, Itamaraty confirmed Lula's trip to China, adding that he would also meet with Chinese premier Li Qiang and National People's Congress chairman Zhao Leji. A week later, New Development Bank (NDB), whose headquarters are in Shanghai, elected Brazilian former president Dilma Rousseff as its new CEO after president Lula made his official appointment. On 24 March, however, due to health issues Lula canceled his trip which was later rescheduled for 11–14 April. As part of a separate high-level business forum between Brazilian and Chinese officials and hundreds of business people in Beijing, both countries announced on 29 March they were starting to trade in their own currencies (the Real and the Renmimbi) instead of in the US dollar. In April 2023, President Lula, who was accompanied by many of his cabinet ministers, Brazilian state governors and lawmakers, met with Chinese deputy foreign minister Xie Feng upon their arrival in Shanghai, where Lula also attended Brazilian former president Dilma Rousseff inauguration as the new NDB CEO, visited a Huawei center and spoke with several Chinese chairpeople including BYD CEO Wang Chuanfu and China Communications Construction Company (CCCC) CEO Wang Tongzhou.
==== Red-dome Cave 67: more royal dedications ==== Another nearby cave, the Red-domed Cave A (Cave 67) also has inscriptions mentioning a list of donors including a queen and six kings, among them Suvarnapuspa (ruled 600–625 CE) and his son Suvarnadeva (ruled 625–648 CE). Also included in the inscriptions are the names of King Tottika and his wife Svayamprabha (a Sanskrit name), who also appear in the Maya Cave of the Second Group (Cave 205), suggesting proximity in time of these two caves. The epigraphy also suggest dates later than the Cave of the Painters, with its more ancient inscription about the "painter Tutuka". The Red-dome cave contained a library in which were found very old manuscripts, including one of the oldest known manuscripts in Sanskrit.
Sources: en.wikipedia.org
Kamal al-Labwani, a prisoner of conscience who had three years added to his 12-year sentence for allegedly "broadcasting false or exaggerated news which could affect the morale of the country", on account of remarks he was alleged to have made in his prison cell. Nabil Khlioui, an alleged Islamist from Deir ez-Zor, who with at least 10 other Islamists, most are presumed to be from Deir al-Zour, remained in incommunicado detention without charge or trial at the end of 2009. Mashaal Tammo, the killed spokesperson for the unauthorized Kurdish Future Current group, who was 'held incommunicado for 12 days and charged with "aiming to provoke civil war or sectarian fighting", "conspiracy" and three other charges commonly brought against Kurdish activists, charges that could lead to the death penalty. Twelve leaders of a prominent gathering of opposition groups, the Damascus Declaration, continue to serve 30-month prison terms. Among those detained is Riad Seif, 62, a former member of parliament who is in poor health. Habib Saleh was sentenced to three years in jail for "spreading false information" and "weakening national sentiment" in the form of writing articles criticizing the government and defending opposition figure Riad al-Turk. One released prisoner was Aref Dalila. He had served seven of the ten years in his prison sentence, much of it in solitary confinement and in increasingly poor health, for his involvement in the so-called "Damascus Spring" before being released by a presidential pardon.
== Current application of LED light therapy == Red light therapy, utilising red LED lights, originated from techniques intended to enhance plant growth in space and aid in astronauts' wound healing. Primarily used in dermatology, it enhances skin conditions by stimulating mitochondria, thereby increasing collagen production and blood circulation while reducing inflammation. Additionally, it plays a crucial role in photodynamic therapy, where it combines with photosensitive drugs to target and destroy cancerous cells through a light-induced chemical reaction. Blue light therapy is also a common LED light therapy to treat acne, skin cancer, and depression. While blue light therapy has similar mechanisms for skin enhancement as red light therapy, its usage for photodynamic therapies in treating cancer are slightly different. Blue light therapy stimulates immune system defences, destroys blood vessels that help cancer cells grow, and causes cell death by reacting with oxygen. It also prevents skin cancer and metastasis by removing precancerous and cancerous skin lesions. Application of red and blue LED light for photodynamic treatments are generally safe and can be used to treat different cancers. However, they may differ in the efficiency and response. For instance, In the treatment of Gorlin syndrome, a genetic disorder predisposed to cancer, studies have shown that blue light therapy achieves a higher tumor clearance rate and induces less pain than red light therapy.
=== Reported end of outbreak: August–September 2022 === On 5 August 2022, the country reported that it had not seen a fever case for seven consecutive days, and that every fever case had recovered. On 8 August, plans were announced to convene the Supreme People's Assembly in September, moving its members out of isolation. A separate review meeting to discuss a "change in direction" in pandemic response was also announced. On 11 August, Kim Jong Un's sister, Kim Yo Jong, stated that her brother had had a fever, implying that he had COVID-19 at one point. She also blamed South Korea for the COVID-19 outbreak in the country, claiming that it sent contaminated anti-Pyongyang leaflets to spread the disease. North Korean media reports indicate that the population have resumed regular activity. On August 25, several sources told NK News that North Korea could possibly allow foreigners into North Korea for the first time since 2020, likely after the 20th National Congress of the Chinese Communist Party later in 2022. In September, however, Kim Jong Un flagged the first rollout of vaccines in November and warned that COVID-19 could reappear in the winter months. The mass vaccination program started in the border areas in late September, making North Korea the last country in the world other than Eritrea to have a mass vaccination program against COVID-19.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.